scholarly journals Immune Biomarkers in the Prediction of Future Myocardial Infarctions in People With Human Immunodeficiency Virus

2019 ◽  
Vol 70 (8) ◽  
pp. 1764-1767
Author(s):  
Janine M Trevillyan ◽  
Carlee Moser ◽  
Judith S Currier ◽  
Tamer Sallam
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cardiovascular Risk ◽  
High Sensitivity ◽  
Myocardial Infarctions ◽  
Control Analysis ◽  
Retrospective Case ◽  
Reactive Protein ◽  
Immune Biomarkers ◽  
Immunodeficiency Virus ◽  
Case Control Analysis

Abstract In a retrospective case control analysis, following adjustments for high-sensitivity C-reactive protein (hsCRP), traditional cardiovascular risk factors, and the CD4/CD8 T-cell ratio, higher lipopolysaccharide-binding protein (LBP) was associated with future myocardial infarctions in hsCRP human immunodeficiency virus (HIV). LBP may be a marker of cardiovascular risk with utility in HIV.

scholarly journals Effect of Intercurrent Infections and Vaccinations on Immune and Inflammatory Biomarkers Among Human Immunodeficiency Virus-Infected Adults on Suppressive Antiretroviral Therapy

2015 ◽  
Vol 2 (2) ◽  
Author(s):  
Darrell H. S. Tan ◽  
Leah Szadkowski ◽  
Janet Raboud ◽  
Tae Joon Yi ◽  
Brett Shannon ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiretroviral Therapy ◽  
High Sensitivity ◽  
Inflammatory Biomarkers ◽  
C Reactive Protein ◽  
Future Studies ◽  
Hiv Rna ◽  
Reactive Protein ◽  
Immunodeficiency Virus ◽  
The Impact

Abstract We used generalized estimating equations to quantify the impact of recent vaccination or intercurrent infections on immune and inflammatory biomarkers among 144 human immunodeficiency virus (HIV)-infected adults with HIV RNA < 50 copies/mL on antiretroviral therapy. These events were associated with a 2.244 µg/mL increase in high sensitivity C-reactive protein and should be routinely assessed in future studies.

scholarly journals An Observational Case-Control Study to Determine Human Immunodeficiency Virus and Host Factor Influence on Biomarker Distribution and Serodiagnostic Potential in Adult Pulmonary Tuberculosis

2019 ◽  
Vol 4 (2) ◽  
pp. 57 ◽  
Author(s):  
Khayriyyah Mohd Hanafiah ◽  
Mary Garcia ◽  
David Anderson
Keyword(s):  
Human Immunodeficiency Virus ◽  
Pulmonary Tuberculosis ◽  
Multinomial Logistic Regression ◽  
Host Factors ◽  
Reactive Protein ◽  
Diagnostic Potential ◽  
Immune Biomarkers ◽  
Immunodeficiency Virus ◽  
Complex Relationships ◽  
Culture Count

Influence of host factors, including human immunodeficiency virus (HIV) co-infection, on the distribution and diagnostic potential of previously evaluated biomarkers of pulmonary tuberculosis (PTB), such as anti-antigen 60 (A60) immunoglobulin (Ig) G, anti-A60 IgA, and C-reactive protein (CRP), remain unclear. Anti-A60 IgG, anti-A60 IgA, and CRP in PTB and non-PTB patient sera (n = 404, including smear-positive/negative, culture-positive (SPCP/SNCP) and HIV+ve/−ve) were measured by enzyme-linked immunoassay and statistically analysed. In multinomial logistic regression, expectoration, chest pain, wasting, and culture count positively associated with CRP (p < 0.001), while smear count positively associated with anti-A60 IgG (p = 0.090). Expectoration and enlarged lymph nodes negatively associated with anti-A60 IgA (p = 0.018). Biomarker distribution and diagnostic potential varied significantly by symptoms and bacilli burden, and across different PTB subpopulations. CRP was correlated poorly with anti-A60 antibodies, while anti-A60 IgA and IgG were correlated in non-tuberculosis (TB) and SPCP patients (p < 0.001). When combined, anti-A60 IgG and CRP best discriminated SPCP/HIV−ve from non-TB (AUC: 0.838, 95% CI: 0.783–0.894), while anti-A60 IgA and CRP performed best in discriminating HIV+ve PTB from non-TB (AUC: 0.687, 95% CI: 0.598–0.777). Combined CRP and anti-A60 antibodies had significantly reduced accuracy in SNCP and SNCP/HIV+ve compared to SPCP/HIV−ve subpopulations. The complex relationships between host factors and biomarkers suggest their limited utility, especially in SNCP/HIV+ve subpopulations, highlighting the importance of examining host response and immune biomarkers across relevant patient subpopulations.

scholarly journals Management of Esophageal Carcinoma Associated with Cirrhosis: A Retrospective Case-Control Analysis

2009 ◽  
Vol 2009 ◽  
pp. 1-5 ◽  
Author(s):  
Florence Trivin ◽  
Eveline Boucher ◽  
Elodie Vauléon ◽  
Isabelle Cumin ◽  
Elisabeth Le Prisé ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Esophageal Carcinoma ◽  
Case Control ◽  
Control Analysis ◽  
Retrospective Case ◽  
Compensated Cirrhosis ◽  
Dismal Prognosis ◽  
Chemotherapy Dose ◽  
Case Control Analysis ◽  
Control Study

Objectives. Esophageal carcinoma and cirrhosis have the overlapping etiologic factors.Methods. In a retrospective analysis conducted in 2 Breton institutions we wanted to asses the frequency of this association and the outcome of these patients in a case-control study where each case (cirrhosis and esophageal cancer) was paired with two controls (esophageal cancer).Results. In a 10-year period, we have treated 958 esophageal cancer patients; 26 (2.7%) had a cirrhosis. The same treatments were proposed to the 2 groups; cases received nonsignificantly different radiation and chemotherapy dose than controls. Severe toxicities and deaths were more frequent among the cases. At the end of the treatment 58% of the cases and 67% of the controls were in complete remission; median and 2-year survival were not different between the 2 groups. All 4 Child-Pugh B class patients experienced severe side effects and 2 died during the treatment.Conclusions. This association is surprisingly infrequent in our population! Child-Pugh B patients had a dismal prognosis and a bad tolerance to radiochemotherapy; Child-Pugh A patients have the same tolerance and the same prognosis as controls and the evidence of a well-compensated cirrhosis has not modified our medical options.

Metabolic syndrome in human immunodeficiency virus-infected patients

2018 ◽  
Vol 29 (11) ◽  
pp. 1089-1097 ◽  
Author(s):  
M Duro ◽  
MC Manso ◽  
S Barreira ◽  
I Rebelo ◽  
R Medeiros ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Acute Infection ◽  
Density Lipoprotein ◽  
Total Antioxidant Status ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Infection Treatment ◽  
Immunodeficiency Virus ◽  
Total Antioxidant

The objective of this study was to investigate the factors underlying the development of metabolic syndrome (MetS) in HIV-infected patients. Two hundred and sixty-six clinical cases were selected for a retrospective study. The sample was classified using the Adult Treatment Panel III guidelines and the identification of risk or protective factors associated with MetS evaluated via multivariate logistic or multinomial regressions. HIV-infected individuals diagnosed with MetS tend to be older, overweight, or obese (85% have a BMI ≥ 25), with a waist circumference > 90 cm (96.5 [88.8–105.5] cm, median [interquartile range]). Blood testing these individuals revealed high fasting levels of insulin (8.1 [5.8–21.6] pg/ml), glucose (98.0 [84.0–116.0] mg/dl), triglycerides (201.0 [142.0–267.3] mg/dl), and high-density lipoprotein cholesterol (36.5 [29.8–43.3] mg/dl) in addition with higher levels of inflammatory mediators such as high-sensitivity C-reactive protein (2.5 [1.0–4.9] mg/dl) and interleukin-6 (3.4 [2.8–3.8] pg/ml). The likelihood of HIV-infected individuals who are virally suppressed developing MetS is about 60% higher than those with acute infection. Treatment with nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs) increases the chance of developing MetS by around 2.4 times. Individuals with a lower antioxidant capacity (total antioxidant status [TAS] <1.33) have a 2.6 times higher risk of developing MetS. HIV-related chronic inflammation, a low TAS, and treatment with NRTIs in association with PIs are additional MetS risk factors.

scholarly journals Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus‐associated cardiovascular risk

2019 ◽  
Vol 176 (7) ◽  
pp. 879-889 ◽  
Author(s):  
Kirk A. Taylor ◽  
Erica Smyth ◽  
Francesca Rauzi ◽  
Maddalena Cerrone ◽  
Akif A. Khawaja ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cardiovascular Risk ◽  
Antiretroviral Therapy ◽  
Platelet Function ◽  
Immunodeficiency Virus
Sign in / Sign up

Export Citation Format

Share Document